Phospho-ERK and AKT status, but not <it>KRAS </it>mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

Phospho-ERK and AKT status, but not <it>KRAS </it>mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

<p>Abstract</p> <p>Background</p> <p><it>KRAS </it>mutations may predict poor response to radiotherapy. Downstream events from <it>KRAS</it>, such as activation of <it>BRAF</it>, AKT and ERK, may also confer prognostic information but...

Full description

Bibliographic Details
Main Authors: Calvo Benjamin F, Funkhouser William K, Deal Allison M, Trembath Dimitri, Davies Janine M, Finnegan Timothy, Weck Karen E, Tepper Joel E, O'Neil Bert H
Format: Article
Language:English
Published: BMC 2011-09-01
Series:Radiation Oncology
Subjects:
Rectal cancer
KRAS analysis
phosphoERK
phosphoAKT
radiation response
Online Access:http://www.ro-journal.com/content/6/1/114

Internet

http://www.ro-journal.com/content/6/1/114

Similar Items